Apyx Medical (APYX) Equity Average (2011 - 2026)

Apyx Medical has reported Equity Average for 16 years, with the latest figure at $13.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 9.58% year-over-year to $13.7 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (up 9.58% YoY), and the FY2025 full-year result was $14.4 million, down 30.01% from the prior year.
• Equity Average for Q1 2026 stood at $13.7 million, up from $10.3 million in the prior quarter.
• The five-year high for Equity Average was $51.9 million in Q1 2022, with the low at $6.8 million in Q3 2025.
• Historically, Equity Average has averaged $26.0 million across 5 years, with a median of $23.7 million in 2024.
• Annual changes were most pronounced in 2024 — Equity Average sank 62.85% — and 2026, when it advanced 9.58%.
• Apyx Medical's Equity Average stood at $40.0 million in 2022, then dropped by 24.37% to $30.3 million in 2023, then slumped by 57.8% to $12.8 million in 2024, then fell by 19.24% to $10.3 million in 2025, then surged by 32.74% to $13.7 million in 2026.
• The last three Equity Average figures came in at $13.7 million (Q1 2026), $10.3 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.